Novo Nordisk's €900 Million Buyback and Oral Wegovy's EU Nod Set the Stage for a Crucial Earnings Report
Published on 07/21/2026 at 14:12 | Redaktion boerse-global.de
Novo Nordisk is sending two strong signals to the market at once: it is aggressively repurchasing its own shares while simultaneously expanding its weight-loss drug portfolio with a landmark regulatory win. The Danish pharmaceutical giant has already bought back nearly 25 million B-shares under its current programme, spending the equivalent of more than €900 million since February. The purchases, executed at an average price of 274.58 Danish kroner each, leave Novo holding 42.1 million treasury shares, or 0.9% of total equity.
The buyback is part of a larger plan announced on 4 February 2026 to retire up to 15 billion kroner in B-shares within twelve months. The latest tranche, running from 6 May 2026 to 1 February 2027, carries a volume of roughly 11.2 billion kroner and is conducted under the standard framework of Article 5 of the EU Market Abuse Regulation. Buybacks typically signal management confidence and can mechanically lift earnings per share, though for a company with a market capitalisation near €195 billion the impact on the overall share count remains modest.
That capital-return story now has a product catalyst alongside it. The European Commission on 15 July 2026 approved the oral Wegovy tablet – a 25-milligram formulation of semaglutide – as the first oral GLP-1 medicine for weight management in the EU. The green light covers patients with obesity (BMI of 30 or higher) and overweight individuals (BMI of 27 or higher) who have at least one weight-related comorbidity. A single-use, ready-to-inject 7.2-milligram pen also received clearance. The approval, the fifth for the oral pill after the US, UK, UAE and Bahrain, was based on the OASIS-4 study in which patients lost on average 17% of their body weight, compared with 3% on placebo, and roughly one in three achieved a loss of at least 20%. The safety profile matched that of the injectable version. Novo plans to roll out the pill in additional European countries during the second half of 2026.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The regulatory tailwind has also caught the attention of analysts. Citi has raised its price target for Novo Nordisk to 330 Danish kroner, lifting the valuation multiple applied to 2027 earnings from 15 times to 16 times. The bank raised its 2026 revenue and operating profit forecasts by 4%–5% and its 2027–2030 earnings-per-share estimates by roughly 7%, while keeping a "Neutral" rating. Citi's upgrade is tied to the strong early uptake of the oral Wegovy pill and is framed around the upcoming second-quarter results, due on 5 August. The bank models Q2 operating profit of 27.2 billion kroner, a 9% decline on a currency-adjusted basis, on revenue of 72.7 billion kroner, down 1% – both figures excluding the 340B effect. Oral Wegovy is expected to contribute around 4 billion kroner ($630 million) to sales. The key question, in Citi's view, is whether Novo will raise its full-year guidance given robust prescription trends, despite competition from Eli Lilly and other GLP-1 developers.
The broader weight-loss drug market provides a supportive backdrop. Valued at $4.21 billion in 2025, the sector is forecast to nearly double to $5.96 billion this year and expand at a compound annual rate of 41.8% to $23.59 billion by 2030. Rising obesity rates globally and the entry of rivals such as Eli Lilly, Pfizer and Roche are both intensifying competition and enlarging the total addressable market.
Yet for all the positive news, Novo Nordisk’s stock remains well below its former highs. The B-share recently traded at €43.27, having risen 7.82% over the past 30 days but still down about 29% from the €60.95 peak reached roughly a year ago. Year-to-date the share has slipped 1.7%. Although the stock has recovered more than 43% from its 52-week low struck in early March, the gap to the 52-week high underlines the distance still to be covered. Some analysts also caution that the growing reliance on cash-pay patients – those paying out of pocket rather than through insurance – represents both an opportunity and a mounting systemic risk to Novo’s business model.
The combination of a multi-billion-kroner share buyback and a major regulatory approval gives Novo a dual narrative of capital discipline and product expansion. Whether that narrative translates into a higher stock price will likely depend on the Q2 numbers and, crucially, on whether management chooses to raise the outlook when it reports early next month.
Ad
Novo Nordisk Stock: New Analysis - 21 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
